TY - JOUR AU - Stefano Pulini, AU - Serena Rupoli, AU - Gaia Goteri, AU - Nicola Pimpinelli, AU - Renato Alterini, AU - Angela Tassetti, AU - Anna Rita Scortechini, AU - Massimo Offidani, AU - Simonetta Mulattieri, AU - Andrea Stronati, AU - Giuliano Brandozzi, AU - Alfredo Giacchetti, AU - Giorgio Mozzicafreddo, AU - Giuseppe Ricotti, AU - Giorgio Filosa, AU - Alberta Bettacchi, AU - Marco Simonacci, AU - Nicolino Novelli, AU - Pietro Leoni, PY - 2007/05/01 Y2 - 2024/03/29 TI - Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas JF - Haematologica JA - haematol VL - 92 IS - 5 SE - Brief Reports DO - 10.3324/haematol.10879 UR - https://haematologica.org/article/view/4443 SP - 686-689 AB - Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I–IIA and IIB–IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs. ER -